Breaking News Instant updates and real-time market news.

ACRX

AcelRx

$2.95

0.025 (0.85%)

, CTSO

CytoSorbents

$12.00

0.05 (0.42%)

04:55
08/23/18
08/23
04:55
08/23/18
04:55

U.S. Department of Defense to hold a symposium

2018 Military Health System Research Symposium will be held in Kissimmee, FL on August 20-23.

ACRX

AcelRx

$2.95

0.025 (0.85%)

CTSO

CytoSorbents

$12.00

0.05 (0.42%)

FLXN

Flexion

$21.61

0.43 (2.03%)

LJPC

La Jolla

$23.60

-0.26 (-1.09%)

MASI

Masimo

$116.31

0.94 (0.81%)

TFX

Teleflex

$247.57

3.86 (1.58%)

TXMD

TherapeuticsMD

$5.63

0.07 (1.26%)

  • 30

    Aug

  • 04

    Sep

  • 05

    Sep

  • 06

    Sep

  • 12

    Sep

  • 20

    Sep

  • 21

    Sep

  • 28

    Oct

ACRX AcelRx
$2.95

0.025 (0.85%)

07/13/18
OPCO
07/13/18
INITIATION
OPCO
Perform
AcelRx initiated with a Perform at Oppenheimer
Oppenheimer analyst Leland Gershell initiated AcelRx with a Perform rating, citing regulatory uncertainty and commercial headwinds. In a note to investors, Gershell says that he "lacks conviction" on Dsuvia and Zalviso's ability to take meaningful share within the large acute pain/injectable opioid treatment market and that he is "cautious" in the near-term on Dsuvia's late-2018 FDA decision in a regulatory and societal atmosphere attuned to opioids' liabilities.
06/12/18
CANT
06/12/18
INITIATION
CANT
Cantor expands Specialty Pharmaceuticals coverage with eight names
Cantor Fitzgerald analyst Brandon Folkes last night rolled out coverage on eight names in the Specialty Pharmaceuticals space. He initiated coverage of AcelRx (ACRX), ANI Pharmaceuticals (ANIP), Biohaven Pharmaceutical (BHVN), Collegium Pharmaceutical (COLL), Emergent BioSolutions (EBS), Eagle Pharmaceuticals (EGRX) and Opiant Pharmaceuticals (OPNT) with Overweight ratings. There is still value to be unlocked in these stocks at current valuations with risk/reward profiles that remain to the upside, Folkes told investors in a research note. His top picks are ANI Pharmaceuticals, Emergent BioSolutions and Collegium Pharmaceutical. The analyst rounded out his coverage with a Neutral rating on Momenta (MNTA), saying the recent share rally puts him on the sidelines "for now."
08/16/18
LTCO
08/16/18
INITIATION
Target $7
LTCO
Buy
AcelRx initiated with a Buy at Ladenburg
Ladenburg analyst Michael Higgins initiated AcelRx with a Buy and $7 price target.
08/16/18
08/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Post Holdings (POST) initiated with an Overweight at Piper Jaffray. 2. Stryker (SYK) initiated with a Buy at BTIG. 3. Aveo Pharmaceuticals (AVEO) initiated with a Buy at H.C. Wainwright. 4. Uxin (UXIN) initiated with a Buy at Goldman Sachs. 5. AcelRx (ACRX) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CTSO CytoSorbents
$12.00

0.05 (0.42%)

FLXN Flexion
$21.61

0.43 (2.03%)

08/08/18
WELS
08/08/18
NO CHANGE
Target $39
WELS
Outperform
Flexion Q2 suggests Zilretta launch proceeding as expected, says Wells Fargo
Wells Fargo analyst David Maris kept his Outperform rating and $39 price target on Flexion, saying the company's Q2 results suggest that Zilretta sales are proceeding according to its plans and in line with his expectations. The analyst points to the management's comments that the overall response on Zilretta from physicians has been positive, adding that its unique product specific Q-code becoming effective as of this July 1st will drive sales growth in the second half of 2018.
06/28/18
06/28/18
INITIATION
Target $39

Buy
Benchmark says Zilretta can be 'best-in-class,' starts Flexion at Buy
As previously reported, Benchmark analyst Bruce Jackson initiated Flexion Therapeutics with a Buy rating and $39 price target, citing his belief that Zilretta can emerge as a "best-in-class" therapy for treating osteoarthritis knee pain. He sees peak sales potential in excess of $750M for the drug, he tells investors in his initiation note.
06/28/18
BNCH
06/28/18
INITIATION
Target $39
BNCH
Buy
Flexion initiated with a Buy at Benchmark
Benchmark started Flexion Therapeutics with a Buy rating and $39 price target.
06/19/18
WELS
06/19/18
NO CHANGE
WELS
Outperform
Flexion to benefit from Anika Therapeutics failed Cingal study, says Wells Fargo
Wells Fargo analyst David Marris tells investors that the failed Phase 3 study by Anika Therapeutics' (ANIK) Cingal product in the treatment of knee osteoarthritis removes a potential threat from Flexion's (FLXN) Zilretta. The analyst contends that the runway for Flexion is now clear as it progresses through its early Zilretta launch phase. Marris keeps his Outperform rating on Flexion.
LJPC La Jolla
$23.60

-0.26 (-1.09%)

05/11/18
COWN
05/11/18
NO CHANGE
Target $50
COWN
Outperform
La Jolla remains undervalued, says Cowen
Cowen analyst Phil Nadeau noted La Jolla reported Q1 results and announced a $125M royalty agreement with HealthCare Royalty Partners. Giapreza entered the market in March and recorded over $800,000 in revenues, and he said it could address a $500M+ opportunity. Nadeau continues to believes La Jolla is undervalued and he reiterated his Outperform rating, though he lowered his price target to $50 from $55 per share.
05/11/18
HCWC
05/11/18
NO CHANGE
Target $72
HCWC
Buy
La Jolla price target lowered to $72 from $83 at H.C. Wainwright
H.C. Wainwright analyst Edward White lowered his price target for La Jolla Pharmaceutical to $72 after the company announced a $125M royalty financing agreement with HealthCare Royalty Partners. The analyst, however, thinks the deal should give investors more confidence in Giapreza's success. He keeps a Buy rating on La Jolla.
08/09/18
RHCO
08/09/18
NO CHANGE
Target $45
RHCO
Buy
La Jolla price target lowered to $45 from $57 at SunTrust
SunTrust analyst Yatin Suneja lowered his price target on La Jolla to $45 after its Q2 sales of Giapreza came in "significantly" below expectations, reflecting the "hurdles of navigating complex hospital adoption". Longer term, the analyst keeps his Buy rating on the shares given his view of Giapreza as a " true value-add in the treatment of septic shock".
07/27/18
HCWC
07/27/18
NO CHANGE
Target $53
HCWC
Buy
La Jolla price target lowered to $53 from $72 at H.C. Wainwright
H.C. Wainwright analyst Edward White lowered his price target for La Jolla Pharmaceutical to $53 as he moves Giapreza out of pipeline estimates and utilizes a sum-of-the-parts analysis. The analyst keeps a Buy rating on the shares.
MASI Masimo
$116.31

0.94 (0.81%)

03/09/18
LEHM
03/09/18
INITIATION
Target $97
LEHM
Overweight
Masimo initiated with an Overweight at Barclays
Barclays analyst Matthew Taylor started Masimo with an Overweight rating and $97 price target. The company has am "impressive history" of innovation, core competencies in engineering/signal processing, and a start-up culture that "make it stand out," the analyst contends. He believes Masimo is gaining share in its core pulse-oximetry market.
05/02/18
PIPR
05/02/18
NO CHANGE
Target $94
PIPR
Neutral
Masimo price target raised to $94 from $91 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target on Masimo to $94 after its Q1 earnings beat and raised guidance for FY18, saying the company's driver shipments in the quarter reflects the ongoing strength of its Signal Extraction Technology - SET - business. The analyst further cites the management's commentary that growth was evident in both the U.S. and the overseas markets while also pointing to the company's expected stock buybacks being favored over large M&A deals. Quirk keeps his Neutral rating on Masimo, stating that despite the better than expected results, the company's risk-reward is balanced at current levels.
03/09/18
03/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Corcept Therapeutics (CORT) initiated with a Buy at B. Riley FBR. 2. Masimo (MASI) initiated with an Overweight at Barclays. 3. Ovid Therapeutics (OVID) initiated with an Overweight at Piper Jaffray. 4. Endocyte (ECYT) initiated with an Outperform at Wells Fargo. 5. Cloudera (CLDR) initiated with a Neutral at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
TFX Teleflex
$247.57

3.86 (1.58%)

08/02/18
PIPR
08/02/18
NO CHANGE
Target $295
PIPR
Overweight
Teleflex distributor issues temporary, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien keeps his Overweight rating and $295 price target on Teleflex after today's 8% drop in the stock price, saying the Q2 revenue miss was the result of supply disruption that should prove to be temporary. The analyst expects the company to deliver on its guidance for FY18 and also sees some "compelling" revenue drivers in FY19 such as Neotract, VSI, Vidacare, Percuvance, and RePlas. O'Brien recommends that investors use today's weakness to begin accumulating a position in Teleflex.
06/22/18
JEFF
06/22/18
NO CHANGE
Target $305
JEFF
Buy
Jefferies confident Teleflex shares can hit $375 by 2020
UroLift, which treats enlarged prostates, continues to exceed expectations and is looking like a "growth game changer" for Teleflex, Jefferies analyst Raj Denhoy tells investors in a research note after hosting management for meetings. Feedback on UroLift continues to support the notion that the 40% growth outlook baked in for this year could prove conservative, the analyst adds. He believes growth is coming from existing practices, which he notes are seeing increased patient volumes. Further, strength in a number of product areas supports Teleflex's outlook for 4% core growth, Denhoy adds. He remains confident that the shares will hit $375 by 2020. The analyst keeps a Buy rating on Teleflex with a $305 price target. The stock in midday trading is up $2.72 to $282.34.
05/14/18
JEFF
05/14/18
NO CHANGE
Target $305
JEFF
Buy
Teleflex price target raised to $305 from $290 at Jefferies
Jefferies analyst Raj Denhoy raised his price target on Teleflex to $305 from $290, telling investors in a research note that the company's 2021 plan largely matched expectations going into its analyst day, with the company's new three-year outlook calling for $15 in EPS, 6%-7% organic growth, 380-480 basis points of adjusted operating margin expansion and a 16%-17.5% tax rate through 2021. The analyst, who has a Buy rating on Teleflex, sees upside beyond these targets, suggesting EPS could grow over the next three years in the mid-to-upper teens.
06/05/18
LEER
06/05/18
NO CHANGE
Target $317
LEER
Outperform
Teleflex price target raised to $317 from $309 at Leerink
Leerink analyst Richard Newitter raised his price target for Teleflex to $317 from $309 after meeting with management as the discussion reinforced his view that over the next several years there is relatively clear line of sight for the company to be an HSD top-line grower while also delivering 350bps-490bps of margin expansion and a mid-teens EPS growth trajectory. The analyst reiterates an Outperform rating on the shares.
TXMD TherapeuticsMD
$5.63

0.07 (1.26%)

06/08/18
CANT
06/08/18
NO CHANGE
Target $26
CANT
Overweight
TherapeuticsMD shares do not reflect value of Imvexxy, says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner views the recent FDA approval of Imvexxy as a major milestone for TherapeuticsMD that sets the company on a course to achieve long-term commercial viability. He reiterates an Overweight rating on the shares with a $26 price target. The investability of TherapeuticsMD stock "has increased considerably," Tanner tells investors in a research note. He believes the current stock price does not fully reflect the value of Imvexxy, "much less that of TX-001."
06/15/18
JPMS
06/15/18
INITIATION
Target $11
JPMS
Overweight
TherapeuticsMD initiated with an Overweight at JPMorgan
JPMorgan analyst Chris Schott started TherapeuticsMD with an Overweight rating and $11 price target. The analyst believes TX-001 and Imvexxy represent "significant" long-term opportunities. He sees peak sales of $750M for TX-001 and thinks Imvexxy can gain 20%-plus of the severe dyspareunia market over time. Schott sees TherapeuticsMD as well positioned in the women's health space.
08/14/18
CANT
08/14/18
NO CHANGE
Target $27
CANT
Overweight
Cantor raises TherapeuticsMD target to $27 on Annovera approval
Cantor Fitzgerald analyst William Tanner raised his price target for TherapeuticsMD to $27 from $26 following the approval of Annovera, which he says "provides another leg to the TXMD stool." The company's acquisition of commercial rights to Annovera should appeal to investors, Tanner tells investors in a research note. He believes the product is "clearly complementary" to the emerging women's health franchise. The analyst thinks he next 12-18 months could be a period of positive stock performance if TherapeuticsMD executes on the commercial front.
06/05/18
STFL
06/05/18
NO CHANGE
Target $20
STFL
Buy
Stifel has 'high confidence' in TherapeuticsMD after analyst day
Stifel analyst Annabel Samimy said he left TherapeuticsMD's analyst day with "high confidence" in the launch of Imvexxy and the company's broader commercial strategy ahead of the upcoming expected approval and subsequent launch of TX001HR. The analyst reiterates his Buy rating and $20 price target on TherapeuticsMD shares and "strongly" urges adding to positions at current "depressed levels."

TODAY'S FREE FLY STORIES

JCP

J.C. Penney

$0.93

0.022 (2.42%)

, DDS

Dillard's

$56.57

0.25 (0.44%)

13:29
05/25/19
05/25
13:29
05/25/19
13:29
Periodicals
Target stock triumphs in brutal week for retail, Barron's says »

Earnings season has been…

JCP

J.C. Penney

$0.93

0.022 (2.42%)

DDS

Dillard's

$56.57

0.25 (0.44%)

KSS

Kohl's

$51.11

-0.04 (-0.08%)

JWN

Nordstrom

$33.50

-0.31 (-0.92%)

M

Macy's

$21.00

-0.27 (-1.27%)

TGT

Target

$81.57

2.17 (2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

JPM

JPMorgan

$109.78

1.14 (1.05%)

, AKZOY

AkzoNobel

$0.00

(0.00%)

13:24
05/25/19
05/25
13:24
05/25/19
13:24
Periodicals
Microsoft, JPMorgan among dividend champions, Barron's says »

Among the companies that…

JPM

JPMorgan

$109.78

1.14 (1.05%)

AKZOY

AkzoNobel

$0.00

(0.00%)

XOM

Exxon Mobil

$74.12

0.33 (0.45%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

CMWAY

Commonwealth Bank of Australia

$0.00

(0.00%)

SIEGY

Siemens

$0.00

(0.00%)

T

AT&T

$32.29

0.15 (0.47%)

RDS.A

Royal Dutch Shell

$63.29

0.84 (1.35%)

RHHBY

Roche

$0.00

(0.00%)

NVS

Novartis

$87.49

3.03 (3.59%)

BHP

BHP Group

$52.47

1.18 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 29

    May

  • 29

    May

  • 31

    May

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 05

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 20

    Jun

  • 23

    Jun

  • 16

    Jul

  • 24

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

GM

General Motors

$35.13

0.01 (0.03%)

, TSLA

Tesla

$190.80

-4.7 (-2.40%)

13:19
05/25/19
05/25
13:19
05/25/19
13:19
Periodicals
Tesla stock in trouble, Barron's says »

Tesla (TSLA) stock is the…

GM

General Motors

$35.13

0.01 (0.03%)

TSLA

Tesla

$190.80

-4.7 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

  • 05

    Jun

  • 11

    Jun

  • 01

    Aug

RNLSY

Renault

$0.00

(0.00%)

13:14
05/25/19
05/25
13:14
05/25/19
13:14
Periodicals
Renault stock may rally, Barron's says »

Shares of French auto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

, DWDP

DowDuPont

$31.10

0.16 (0.52%)

13:11
05/25/19
05/25
13:11
05/25/19
13:11
Periodicals
DowDuPont spinoff a new agriculture stock, FMC safer bet, Barron's says »

The crop-protection and…

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

DWDP

DowDuPont

$31.10

0.16 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 25

    Jun

MGM

MGM Resorts

$25.55

0.19 (0.75%)

13:03
05/25/19
05/25
13:03
05/25/19
13:03
Periodicals
MGM Resorts looks like an attractive gambling play, Barron's says »

MGM Resorts (MGM) stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

PYPL

PayPal

$109.82

-0.09 (-0.08%)

, AXP

American Express

$119.52

1.07 (0.90%)

12:30
05/25/19
05/25
12:30
05/25/19
12:30
Periodicals
Big tech failed to dethrone credit cards, Barron's says »

Rather than being cut out…

PYPL

PayPal

$109.82

-0.09 (-0.08%)

AXP

American Express

$119.52

1.07 (0.90%)

MA

MasterCard

$251.40

1.57 (0.63%)

V

Visa

$162.72

1.2 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 03

    Jun

  • 05

    Jun

  • 06

    Jun

  • 11

    Jun

  • 25

    Jun

  • 13

    Nov

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

, GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

07:20
05/25/19
05/25
07:20
05/25/19
07:20
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

AMBA

Ambarella

$38.28

1.07 (2.88%)

ON

ON Semiconductor

$17.68

-0.235 (-1.31%)

NKE

Nike

$82.12

-0.51 (-0.62%)

ADDYY

Adidas

$0.00

(0.00%)

UAA

Under Armour

$23.54

0.075 (0.32%)

UA

Under Armour

$20.91

0.08 (0.38%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

VMC

Vulcan Materials

$126.28

1.25 (1.00%)

FLR

Fluor

$29.04

0.18 (0.62%)

ACM

Aecom

$31.56

-0.03 (-0.09%)

X

U.S. Steel

$13.63

-0.08 (-0.58%)

AKS

AK Steel

$2.00

-0.155 (-7.21%)

NUE

Nucor

$51.12

-0.27 (-0.53%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$12.85

0.11 (0.86%)

F

Ford

$9.83

-0.02 (-0.20%)

GM

General Motors

$35.13

0.01 (0.03%)

HMC

Honda

$25.45

0.175 (0.69%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$118.54

1.16 (0.99%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 03

    Jun

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 19

    Jun

  • 19

    Jun

  • 23

    Jun

  • 09

    Jul

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 23

    Oct

  • 27

    Oct

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$3.88

(0.00%)

16:36
05/24/19
05/24
16:36
05/24/19
16:36
Conference/Events
Fennec management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 18

    Jun

TD

Toronto-Dominion

$56.66

0.65 (1.16%)

16:35
05/24/19
05/24
16:35
05/24/19
16:35
Syndicate
Breaking Syndicate news story on Toronto-Dominion »

Toronto-Dominion files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
05/24/19
05/24
16:30
05/24/19
16:30
Options
Preliminary option volume of 15.7M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.